BR-1019(BR-1019) - 在研适应症：原发性高血压，2型糖尿病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

心血管疾病内分泌与代谢疾病

在研适应症

原发性高血压2型糖尿病

非在研适应症-

原研机构

Boryung Corp.

在研机构

Boryung Corp.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 BR-1019 相关的临床试验

NCT06636877 / Active, not recruiting临床1期

A Randomized, Open-label, Single Dose, Two-way Replicate Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers

The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-3" and "BR1019-2" in healthy volunteers

开始日期2024-10-23

申办/合作机构

Boryung Corp.

NCT06226727 / Completed临床1期

A Randomized, Open-label, Single Dose, Two-way Replicate Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2" in Healthy Volunteers

The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers

开始日期2024-02-14

申办/合作机构

Boryung Corp.

NCT05875259 / Completed临床1期

A Randomized, Open-label, Multiple-dose, 6-sequence, 3-treatment, 3-period, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects

The purpose of this study is to evaluate the pharmacokinetic interaction and safety between BR1019-1 and BR1019-2 in healthy adult subjects.

开始日期2023-05-13

申办/合作机构

Boryung Corp.

100 项与 BR-1019 相关的临床结果

登录后查看更多信息

100 项与 BR-1019 相关的转化医学

登录后查看更多信息

100 项与 BR-1019 相关的专利（医药）

登录后查看更多信息

100 项与 BR-1019 相关的药物交易

登录后查看更多信息